Deponit

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deponit

Property Description
Active ingredient Nitroglycerin (Glyceryl trinitrate)
Form Transdermal patch (Sustained-release system)
Pharmacological class Vasodilator, Organic nitrate
General purpose Antianginal action (balancing oxygen supply/demand)
Origin Synthetic compound

Deponit: Classification and Active Composition

Deponit is a prescription-only medicinal product classified as an Antianginal agent and a Vasodilator, belonging to the class of organic nitrates. The sole active ingredient in this single-ingredient product is the chemical compound Nitroglycerin, formally identified as Glyceryl trinitrate (GTN). This synthetic compound is structurally defined by its organic nitrate classification. This designation defines its fundamental role in managing conditions related to the heart’s vascular needs.


What Type of Form is the Deponit Transdermal System?

The physical form of the medicine is a transdermal patch, or transdermal system, which is specifically designed for systemic delivery across the skin. The patch is engineered as a sustained-release preparation, where the active Nitroglycerin is embedded within a polymer matrix and adhesive layer. This design ensures that the active compound is released at a uniform, controlled rate over an extended duration. The transdermal route of administration is a differentiating factor, promoting continuous, passive drug absorption rather than relying on oral intake.


What is the General Purpose of a Nitroglycerin Vasodilator?

The general purpose of a Nitroglycerin vasodilator is to achieve a more favorable balance between the heart's oxygen requirements and the oxygen it receives. The core action is the relaxation of vascular smooth muscle in the veins and arteries, which initiates systemic vasodilation. This vasodilation acts to reduce the amount of blood returning to the heart, which effectively decreases the cardiac workload. This mechanism is fundamental to its role as an antianginal agent and is typically used in a scenario where continuous, preventative management of heart-related oxygen imbalance is required.

What side effects are possible with Deponit?

Possible side effects and safety information

The official safety profile for the Deponit transdermal system (Nitroglycerin) is primarily characterized by effects related to its potent vasodilator action and the local application site.

Adverse Reaction Frequency Classification

Adverse reactions are classified according to frequency categories defined in official regulatory labeling:

  • Very Common: Headache (often referred to as nitrate-induced headache, particularly at the start of treatment).
  • Common: Dizziness, Nausea, Vomiting, Hypotension (low blood pressure), Tachycardia (increased heart rate), Flushing, and Application site reactions (such as redness, itching, or burning).
  • Rare: Syncope (fainting), which is often related to severe hypotension.

System-Organ-Class Groupings and Serious Reactions

The documented adverse effects affect several major physiological systems, including Nervous System Disorders (headache, dizziness), Vascular Disorders (hypotension, flushing), and Skin and Subcutaneous Tissue Disorders (application site reactions, allergic contact dermatitis).

Serious Adverse Reactions explicitly listed in regulatory information include severe hypotension (potentially leading to circulatory collapse), Methemoglobinemia, and Exfoliative Dermatitis, though these are very rare.

Time-Related Safety Patterns and Limitations

Adverse effects such as headache are often most common at the start of treatment and may lessen with continued use. Due to the risk of tolerance (reduced effect), regulatory documents emphasize that continuous, long-term application without a patch-free interval is a safety concern. The product is strictly contraindicated for individuals taking Phosphodiesterase Type 5 (PDE5) inhibitors (e.g., sildenafil) due to the risk of severe, life-threatening hypotension.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of the Nitroglycerin transdermal system (Deponit) is officially classified in regulatory labeling as an extreme extension of the drug’s vasodilating effects, necessitating immediate medical attention. The presentation is driven by severe hemodynamic instability.

Documented Manifestations

Official prescribing information documents that overdose may present with signs including profound hypotension, syncope, and paradoxical bradycardia. Other clinical manifestations listed are a persistent throbbing headache, confusion, visual disturbances, diaphoresis, nausea, and vomiting. Overdose can progress to life-threatening systemic outcomes, specifically Methemoglobinemia, significantly increased intracranial pressure, seizures, and, in severe cases, coma or death.

Emergency Response and Management

Immediate medical attention must be sought for any suspected overdose. Emergency services must be contacted immediately if the affected person collapses, has a seizure, or has trouble breathing. Regulatory documents confirm that no specific antagonist or antidote to the primary vasodilator effects of nitroglycerin is known. Therefore, management is strictly supportive. This treatment involves immediate removal of the transdermal patch and procedures aimed at increasing the central fluid volume, which may include passive elevation of the patient's legs or intravenous infusion of normal saline. The use of powerful vasoconstrictor drugs like epinephrine is noted in the labeling as potentially doing more harm than good in managing the hypotension. Special consideration for the hazard of fluid expansion is warranted for patients with underlying renal disease or congestive heart failure.

Therapeutic Uses of Deponit

What Deponit Treats: Main Uses and Benefits

The Deponit transdermal system is commonly used across conditions involving episodic or fluctuating manifestations that require consistent therapeutic support. Its core role is the prevention of angina episodes associated with coronary artery disease (CAD). This makes it applicable within clinical settings that involve the prophylaxis of Chronic Stable Angina Pectoris and conditions where functional stability becomes affected (CAD).


Used for Conditions with Episodic Discomfort

This patch is commonly used to help with conditions characterized by periods of heightened symptoms. It is relevant when supportive symptom management is appropriate for symptoms related to physical discomfort that interfere with daily functioning and require continuous, proactive management.

Supporting Day-to-Day Functional Stability

The primary therapeutic benefit is that it helps address symptom clusters that may become intense or disruptive by contributing to easing the overall symptom load. It assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations during symptomatic periods. It supports patients during episodes of heightened discomfort by easing distress.

Quick Fact: Relevant for easing symptoms related to heightened physiological activity

Regulatory References

  1. NIH MedlinePlus overview on Nitroglycerin Transdermal Patch

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Deponit

The eligibility profile for Deponit (Nitroglycerin Transdermal System) is defined by official regulatory criteria that specify the approved population and list formal contraindications.

Eligibility Scope Regulatory Status
Populations Allowed Adults for the prevention of angina pectoris.
Populations Contraindicated Hypersensitivity to nitroglycerin, organic nitrates, or the patch adhesive. Concurrent use of PDE5 inhibitors (e.g., sildenafil, tadalafil) or riociguat.
Prohibited Conditions Marked Anaemia, Raised Intracranial Pressure, Acute Circulatory Failure (shock), or Myocardial Insufficiency due to Obstruction (e.g., Aortic Stenosis).
Age-Related Rules Paediatric Population (Children): Safety and efficacy have not been established; use is not recommended.
Conditional Use Pregnancy: Use with caution (FDA Category C), only if considered absolutely essential. Severe Hypotension or Severe Hypovolaemia requires caution and monitoring.

Regulatory documents establish absolute prohibitions based on drug interactions and specific pre-existing conditions, classifying these groups as strictly non-eligible. For other groups, such as children and those with hypotension, documentation restricts eligibility by stating that use is either not established or requires enhanced caution.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Deponit


Interaction scope

Medicinal product categories with documented interactions: Phosphodiesterase type-5 (PDE5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Antihypertensive Agents, Hypotension-inducing Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Specific interacting medicines (if explicitly listed): Sildenafil, Tadalafil, Vardenafil, Riociguat, Dihydroergotamine, Amifostine, Acetylsalicylic Acid (Aspirin), Alcohol (Substance Interaction).

Mechanistic basis of interactions (only if stated in label): Pharmacodynamic potentiation of the hypotensive effect, and modification of co-administered drug concentration (increase in Dihydroergotamine bioavailability).

Timing-based interaction rules (if applicable): No specific mandatory separation window for co-administered medicines is documented in the regulatory text.

Population-specific interaction notes (if applicable): No specific cautions regarding interaction severity being heightened in particular populations are explicitly documented in the interaction section of the official label.

Interaction-related restrictions: Contraindicated combinations are explicitly listed in regulatory labeling.


Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Absolute Contraindication (Major severity for certain combinations); Use with Caution (Implied for agents with additive hypotensive effects).

Regulatory basis (EMA / FDA / etc.): Based on official findings documented in FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).

Interaction-context constraints (as defined in official documents): The primary constraint is the potentiation of the vasodilating effect; a secondary constraint is the pharmacokinetic modification of Dihydroergotamine.


Resulting interaction structure

Official interaction statements:

  • Co-administration with Phosphodiesterase type-5 (PDE5) inhibitors (e.g., Sildenafil) is contraindicated due to the risk of severe hypotension and cardiovascular collapse.
  • Concomitant use with the soluble guanylate cyclase (sGC) stimulator Riociguat is also a contraindicated combination.
  • The combination with antihypertensive agents (e.g., calcium channel blockers, beta-blockers) may result in officially documented additive blood pressure-lowering effects.
  • Alcohol has documented additive vasodilating effects, increasing the risk of orthostatic symptoms.
  • Concurrent use may increase the bioavailability of Dihydroergotamine.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), excluding Aspirin, may diminish the officially documented therapeutic response.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product's interaction structure primarily around its core pharmacodynamic action as a potent vasodilator, which necessitates mandatory absolute contraindications with other significant vasodilators. The profile consistently outlines the risk of additive hypotensive effects with co-administered blood pressure-lowering medications, alongside specific documentation of a pharmacokinetic alteration regarding the bioavailability of Dihydroergotamine. These constraints strictly outline co-administration restrictions for patients using the transdermal system.

Mechanism of Action

Molecular Bioactivation and NO Signaling

The mechanism of Deponit begins with its transformation from a prodrug into the active signaling molecule, Nitric Oxide (NO). This conversion is catalyzed primarily by the enzyme Mitochondrial Aldehyde Dehydrogenase 2 ( ALDH2) within the vascular cells. The resulting NO then binds to and activates Soluble Guanylate Cyclase ( sGC), initiating the key cascade that raises levels of the second messenger, cGMP.


Vascular Smooth Muscle Relaxation and Hemodynamic Effect

The increase in cGMP triggers a cascade that leads to the dephosphorylation of myosin light chains, causing the relaxation of vascular smooth muscle. This widespread vasodilation primarily affects the venous system, primarily reducing the volume of blood returning to the heart (preload). This mechanical unloading of the heart is the core physiological consequence, as it results in a reduced myocardial oxygen demand.


Mechanistic Constraint: Nitrate Tolerance

The mechanism is functionally constrained by the occurrence of Nitrate Tolerance. This phenomenon is a functional limitation linked to the desensitization or impaired function of the ALDH2 enzyme, which results in the failure to generate the required Nitric Oxide signal.

Dosage and Administration Information

Deponit is a transdermal patch intended for once-daily application to the skin. Accurate adherence to the application schedule and technique is mandatory.

Official Administration Guidelines

Feature Instruction
Route & Frequency Dermal (Transdermal patch), once daily
Dosing Initiate with one patch daily. Dosage may be increased by a healthcare provider, but the dose should be adjusted gradually. The maximum daily dose is equivalent to 20 mg.
Timing & Interval Apply a new patch each morning. The patch must be removed before going to bed to ensure a 10–12 hour nitrate-free interval every 24 hours. This interval is critical to prevent the development of tolerance.
Preparation Apply the patch to a clean, dry, hairless area of healthy skin, such as the chest, upper arm, or shoulder. Do not use moisturisers or powders on the application site beforehand.
Site Rotation Place each new patch on a different area of skin. Several days must elapse before a patch is applied to the same location again.

Procedural Steps

  1. Wash hands, select a new application site, and ensure the skin is clean and dry.
  2. Tear open the wrapper and remove the patch.
  3. Peel off the backing material to expose the sticky surface.
  4. Press the sticky side firmly onto the skin with the palm of the hand.
  5. Remove the patch at night, ensuring a 10–12 hour patch-free interval. Do not discontinue the treatment abruptly.

If a dose is missed (a patch is forgotten or not changed), the patient should remove the old one and apply a new patch as soon as possible, then continue the regular dosing schedule. Do not apply two patches to compensate for the missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deponit

Evidence for Use in Stable Angina Pectoris

The research on Deponit (nitroglycerin transdermal system) primarily involves short-term randomized controlled trials (RCTs). These studies were used to examine how the patch was studied for adult outpatients with stable angina pectoris, a condition characterized by chest discomfort and functional limitations. Researchers monitored several outcomes related to physical discomfort and activity level. These included measuring changes in how long a person could exercise before experiencing symptoms and the recorded use of sublingual rescue medication.

The findings describe patterns observed in the studies over short time intervals. Research highlights changes measured during the study period, primarily related to exercise capacity. Patterns showing a change in measured exercise duration were observed in some studies when comparing continuous versus intermittent patch application schedules. This research provides insight into short-term changes and how symptoms evolved in the observed populations under controlled conditions.

Understanding Long-Term Studies and Durability

Research has explored the consistency of research findings of the Deponit patch over time, often focusing on how the system can maintain its initial study measurements. Studies conducted during periods of increased symptom activity examined temporary physiological imbalance related to nitrate use. Specific patch-free intervals were examined in research exploring the maintenance of study findings over intermediate timeframes.

The majority of available studies focus on short-term exercise measures, with fewer focusing on extended-duration data. The research regarding measured study parameters related to overall quality of life and the duration of studies that have examined daily use over several weeks or months is limited.

Evidence in Special Populations

Research has explored the use of this patch in certain specific patient groups. The patch was evaluated in some studies involving the older adult population, often alongside individuals with other underlying medical conditions. However, data for certain groups remain insufficient. Research describing specific findings in populations defined by comorbidities or functional limitations may be limited in scope compared to the general adult population.

What Remains Uncertain About Deponit Research

The existing evidence highlights what is known and what is still uncertain about the Deponit patch. A key limitation is that follow-up durations were limited in many of the core efficacy studies, meaning long-term outcomes are not well characterized. Comparative evidence against all possible alternative treatments is lacking in some areas, as some studies focused on comparisons only against placebo. Furthermore, the results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Deponit (FAQ)

Q: How quickly should I feel the effects after applying a Deponit patch?

A: According to official product information, the active ingredient typically reaches a stable level in the blood about two hours after the patch is applied. The transdermal system is designed for prevention of chest pain. The medication is not intended for use in stopping an acute angina attack that is already occurring.


Q: What happens if I forget to remove the Deponit patch after the recommended time?

A: The manufacturer emphasizes that continuous use without a patch-free interval can lead to the rapid development of nitrate tolerance. This means the anti-anginal effect of the medication may be reduced, potentially compromising its ability to prevent chest pain.


Q: What should I do if the side effects of Deponit, like headache, don't go away?

A: Official labeling advises against altering the treatment schedule to manage headaches, as a loss of headache may be linked to a loss of the medication's effectiveness. Headaches are common, especially when starting treatment. If these effects are persistent or severe, individuals are advised to seek guidance from a healthcare provider.


Q: What if my Deponit patch falls off completely before it's time to remove it?

A: If the patch pulls loose or falls off, regulatory patient information instructs users to safely dispose of the used patch by folding it in half with the sticky sides together. It should be replaced according to the directions provided by the prescribing healthcare provider to maintain the treatment schedule.


Q: Can I shower, bathe, or swim while wearing the Deponit patch?

A: The Deponit patch is designed to adhere to clean, dry, intact skin for continuous drug delivery. While the patch is designed to adhere, excessive water exposure or friction may compromise its adherence.


Q: Can the Deponit patch cause a rash or skin irritation where it is applied?

A: Yes, regulatory documents list Application site reactions as a Common side effect. These reactions can include local redness, burning, or itching at the area where the patch is applied.


Q: What is the best way to manage itching or redness at the patch site?

A: To minimize skin irritation and reactions, it is important to rotate the application site every day. A fresh patch should be applied to a new area of skin, and several days should pass before applying the patch to the same location again.


Q: Can Deponit be used by people who also take blood pressure medication?

A: Official information indicates that using Deponit with other blood pressure-lowering agents, such as beta-blockers or calcium channel blockers, may intensify the drop in blood pressure. The concomitant use of these medicines requires specific caution and monitoring by a healthcare provider.


Q: Does heat, like from a heating pad or hot weather, affect how Deponit works?

A: While the product must be stored at room temperature and protected from direct heat, the main concern is localized heat. Excessive heat on the skin, such as from a heating pad, electric blanket, or certain medical treatments, can potentially increase the rate at which the medication is absorbed.


Q: Does a feeling of flushing or redness on the face happen often with Deponit?

A: Yes, a feeling of flushing (redness and warmth on the face or body) is categorized in official labeling as a Common side effect when using the Deponit patch.


Q: What if the edge of the Deponit patch starts to peel up or lift?

A: The patch should be pressed firmly during application to ensure full contact. If it is only partially lifting, it may compromise the full dose delivery. If the patch fully detaches, the individual should consult the instructions provided by their healthcare provider regarding replacement.


Q: Is Deponit used to treat a heart attack in progress?

A: No, official indications state that the Deponit transdermal system is for the prevention of angina pectoris (chest pain). Its benefits have not been established for treating an acute myocardial infarction (heart attack) or immediate heart failure.


Q: Does the Deponit patch prevent all types of angina pain?

A: The patch is indicated for the prevention of angina. However, individuals should be aware that the chronic, continuous use of nitroglycerin without a proper drug-free interval can lead to nitrate tolerance, which may reduce or eliminate the preventative effect over time.


Q: Is it normal to feel dizzy or lightheaded when using the Deponit patch?

A: Yes, Dizziness and lightheadedness are listed as Common side effects. These often occur because the patch can lower blood pressure, especially when changing position (such as standing up quickly).


Q: Why is it important to rotate the application site of the Deponit patch?

A: Rotation is required because application site reactions, such as irritation and redness, are common. Placing each new patch on a different area of skin helps to prevent these local reactions from developing or worsening.


Q: What is the correct area on the body to apply a Deponit patch?

A: The patch should be applied to healthy, undamaged skin that is relatively hairless and free of creases. Recommended application sites include the front or side of the chest, upper arm, thigh, abdomen, or shoulder.


Q: Is it okay to use tape to keep the Deponit patch from falling off?

A: General guidance for transdermal systems suggests that adherence issues may require further securing methods, which should be discussed with a healthcare provider.


Q: Does drinking alcohol affect the safety or effectiveness of Deponit?

A: Official warnings state that the consumption of alcohol can increase the blood pressure-lowering effects of the patch. This can lead to a greater risk of symptoms like dizziness or lightheadedness, particularly when standing up.


Q: Is Deponit safe for use in older adults?

A: While there is no specific information requiring a dose change for older adults, official warnings note that older patients may be more susceptible to severe hypotension (low blood pressure). The use of this medication in older patients is a situation where clinical monitoring is generally recommended.


Q: Is Deponit generally safe for people who have kidney or liver issues?

A: Official information generally indicates that no dosage adjustment is necessary for people with kidney failure. However, caution should be exercised for patients who have severe kidney or liver impairment.


Q: Does Deponit cause dependence or withdrawal symptoms if stopped suddenly?

A: The label notes that chest pain and sudden death have been reported during temporary withdrawal of nitrates, demonstrating the existence of physical dependence. Due to the potential for physical dependence, treatment is generally advised not to be stopped abruptly and should only be managed under the supervision of a healthcare provider.


Q: How can I tell the difference between an allergic reaction and a normal skin reaction to the patch?

A: The label distinguishes between Application site reactions (Common local irritation) and Allergic contact dermatitis (a rare, more severe form of hypersensitivity). A true allergic reaction would be a more serious event; individuals should seek a healthcare provider's assessment to determine the cause of any significant or spreading rash.


Q: Is it possible for Deponit to stop working as well over time (tolerance)?

A: Yes, official documents describe the phenomenon of nitrate tolerance. This is when the medication's effectiveness to prevent chest pain may be lost or significantly reduced if the patch is worn continuously without the prescribed patch-free interval.


Q: What should be done if someone accidentally touches a used Deponit patch?

A: Since the patch contains active medication that can be absorbed through the skin, the exposed area should be washed thoroughly with soap and water immediately. If this occurs, the exposed area should be washed thoroughly, and individuals should be aware of potential signs of overdose, such as a severe headache.


Q: Can Deponit be worn during an MRI or other medical procedures?

A: If the patch contains any metallic components, regulatory warnings state that it must be removed prior to an MRI procedure. This is due to the risk of severe burns or interference with the imaging device. Individuals are generally advised to inform their doctor or technician before any procedure to confirm the necessary steps.

How should Deponit be stored and disposed of?

How to Store and Dispose of Deponit?

Regulatory documents specify strict storage and disposal requirements for the Deponit transdermal system to maintain its stability and prevent accidental exposure to the nitroglycerin it contains.

Storage Requirements

Condition Requirement
Temperature Store below 25 C (77 F). Do not refrigerate or freeze.
Container Keep the patch sealed in its original foil-lined pouch until use.
Protection Store out of direct sunlight and protect from moisture.
Child Safety Keep the medicine out of the sight and reach of children and pets.

Official Disposal Protocol

Used patches must be immediately folded in half with the adhesive sides pressed together and then disposed of safely, inaccessible to children or pets. Unused or expired patches should be disposed of according to local regulations. The product should not be discarded via wastewater due to environmental toxicity.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deponit found in:

A-Z Index: